The recognition highlights the company's scientific innovation and growing impact within the Spanish deep-tech ecosystem.
DNAmic has been selected as one of the Top 100 startups across Spain's Science Parks, recognizing the company's technological innovation, scientific excellence and commercial potential.
The annual recognition highlights emerging companies developing disruptive technologies with the potential to generate significant scientific, industrial and societal impact. DNAmic was selected for its proprietary human protein-based delivery platform designed to enable safer and more efficient in vivo gene and cell therapies.
The distinction reinforces the company's position within Spain's innovation ecosystem and reflects the continued progress achieved since its foundation.
DNAmic will continue working alongside academic institutions, investors and industry partners to advance the next generation of precision delivery technologies.
DNAmic is a biotechnology company developing a next-generation delivery platform for in vivo gene and cell therapies. Built entirely from engineered human proteins, the company's proprietary bioND™ platform is designed to overcome the key limitations of current viral and non-viral delivery technologies by combining efficient intracellular delivery, programmable cargo encapsulation, and cell-specific targeting within a single modular system.
info@dnamic.bio
